[Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]
- PMID: 16315127
- DOI: 10.1055/s-2005-858657
[Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]
Abstract
Introduction: Colonoscopy is currently supposed to be the best screening tool for colorectal cancer. However, the acceptance of the population is very poor although it has been included in screening programs in the German health system since 2002. Therefore, evaluation of additional screening tools seems to be of great interest. Recently testing for fecal occult blood (FOBT), genetic alterations or alterations in tumor metabolism (e.g., tumor M2-PK) are under investigation.
Methods: The use of M2-PK measurement in the feces has been reported in 6 studies until today. The data of these studies were analyzed and critically reviewed.
Results: The overall sensitivity of M2-PK is 77.9% concerning CRC. Specificity ranges from 74.3-83.3%. Overall sensitivity for adenomas is 45.9%, increasing to 61.1% for adenomas > 1 cm. A high percentage of positive results (90.4%) was also observed in patients with chronic inflammatory bowel disease.
Conclusions: Compared to FOBT or genetic testing the M2-PK test seems to be superior for CRC screening. Concerning handling, effectiveness and analysis, M2-PK seems to be a good possibility for large scale-screening of colorectal carcinoma. It might even be used to detect larger adenomas. Elevated levels of M2-PK in patients with acute and/or chronic inflammatory bowel diseases are probably due to proliferation of epithelial cells and leucocytes in the inflammatory area.
Similar articles
-
Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.Anticancer Res. 2007 Jul-Aug;27(4A):1949-52. Anticancer Res. 2007. PMID: 17649802
-
Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.Anticancer Res. 2003 Mar-Apr;23(2A):851-3. Anticancer Res. 2003. PMID: 12820312
-
Stool test for colorectal cancer screening--it's time to move!Clin Lab. 2008;54(11-12):473-84. Clin Lab. 2008. PMID: 19216253 Review.
-
Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.Expert Rev Mol Diagn. 2008 Sep;8(5):579-85. doi: 10.1586/14737159.8.5.579. Expert Rev Mol Diagn. 2008. PMID: 18785806
-
[Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Gastroenterol Hepatol. 2009. PMID: 19577340 Review. Spanish.
Cited by
-
Screening tests for colorectal cancer: a menu of options remains relevant.Curr Oncol Rep. 2006 Nov;8(6):492-8. doi: 10.1007/s11912-006-0079-4. Curr Oncol Rep. 2006. PMID: 17040627 Review.
-
Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.World J Gastroenterol. 2012 Aug 14;18(30):4004-11. doi: 10.3748/wjg.v18.i30.4004. World J Gastroenterol. 2012. PMID: 22912551 Free PMC article.
-
Proteomic analysis of low dose arsenic and ionizing radiation exposure on keratinocytes.Proteomics. 2009 Apr;9(7):1925-38. doi: 10.1002/pmic.200800118. Proteomics. 2009. PMID: 19294697 Free PMC article.
-
Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin.PLoS One. 2012;7(5):e36764. doi: 10.1371/journal.pone.0036764. Epub 2012 May 4. PLoS One. 2012. PMID: 22574221 Free PMC article.
-
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.World J Gastroenterol. 2006 Nov 21;12(43):7007-11. doi: 10.3748/wjg.v12.i43.7007. World J Gastroenterol. 2006. PMID: 17109496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical